nKarta

Nkarta develops genetically-engineered natural killer (NK) cell immunotherapies for cancer using a scalable production platform.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2020
Stage of Initial Investment
Series B
Initial Investment Year
2019